128 related articles for article (PubMed ID: 11862224)
1. Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly.
Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; DiSanto AR
Am J Ther; 1996 Oct; 3(10):688-98. PubMed ID: 11862224
[TBL] [Abstract][Full Text] [Related]
2. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration.
Rohatagi S; Barrett JS; DeWitt KE; Morales RJ
Biopharm Drug Dispos; 1997 Oct; 18(7):567-84. PubMed ID: 9330778
[TBL] [Abstract][Full Text] [Related]
3. Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
Barrett JS; Szego P; Rohatagi S; Morales RJ; De Witt KE; Rajewski G; Ireland J
Pharm Res; 1996 Oct; 13(10):1535-40. PubMed ID: 8899847
[TBL] [Abstract][Full Text] [Related]
4. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
[TBL] [Abstract][Full Text] [Related]
5. Toxicokinetic evaluation of a selegiline transdermal system in the dog.
Barrett JS; DiSanto AR; Thomford PJ; Larsen EM; Palazzolo MJ; Morales RJ
Biopharm Drug Dispos; 1997 Mar; 18(2):165-84. PubMed ID: 9099452
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline.
Mascher HJ; Kikuta C; Millendorfer A; Schiel H; Ludwig G
Int J Clin Pharmacol Ther; 1997 Jan; 35(1):9-13. PubMed ID: 9021435
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride).
Barrett JS; Rohatagi S; DeWitt KE; Morales RJ; DiSanto AR
Am J Ther; 1996 Apr; 3(4):298-313. PubMed ID: 11862265
[TBL] [Abstract][Full Text] [Related]
8. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.
Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; Darnow J; Azzaro AJ; DiSanto AR
J Clin Pharmacol; 1997 Mar; 37(3):238-47. PubMed ID: 9089426
[TBL] [Abstract][Full Text] [Related]
9. Physiologically Based Pharmacokinetic Modeling of Transdermal Selegiline and Its Metabolites for the Evaluation of Disposition Differences between Healthy and Special Populations.
Puttrevu SK; Arora S; Polak S; Patel NK
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 33008144
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
[TBL] [Abstract][Full Text] [Related]
11. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.
Laine K; Anttila M; Huupponen R; Mäki-Ikola O; Heinonen E
Clin Neuropharmacol; 2000; 23(1):22-7. PubMed ID: 10682227
[TBL] [Abstract][Full Text] [Related]
12. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
Kivistö KT; Wang JS; Backman JT; Nyman L; Taavitsainen P; Anttila M; Neuvonen PJ
Eur J Clin Pharmacol; 2001 Apr; 57(1):37-42. PubMed ID: 11372588
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline.
Chen L; Shen B; Wang S; Yu Y; Yan H; Shi Y; Duan G; Xiang P
Drug Test Anal; 2019 Jun; 11(6):898-905. PubMed ID: 30614204
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.
Mahmood I
Clin Pharmacokinet; 1997 Aug; 33(2):91-102. PubMed ID: 9260033
[TBL] [Abstract][Full Text] [Related]
15. Transdermal selegiline.
Patkar AA; Pae CU; Zarzar M
Drugs Today (Barc); 2007 Jun; 43(6):361-77. PubMed ID: 17612708
[TBL] [Abstract][Full Text] [Related]
16. Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.
Palovaara S; Anttila M; Nyman L; Laine K
Eur J Clin Pharmacol; 2002 Jul; 58(4):259-63. PubMed ID: 12136372
[TBL] [Abstract][Full Text] [Related]
17. Selegiline percutaneous absorption in various species and metabolism by human skin.
Rohatagi S; Barrett JS; McDonald LJ; Morris EM; Darnow J; DiSanto AR
Pharm Res; 1997 Jan; 14(1):50-5. PubMed ID: 9034220
[TBL] [Abstract][Full Text] [Related]
18. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
Feiger AD; Rickels K; Rynn MA; Zimbroff DL; Robinson DS
J Clin Psychiatry; 2006 Sep; 67(9):1354-61. PubMed ID: 17017821
[TBL] [Abstract][Full Text] [Related]
19. Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.
Laine K; Anttila M; Helminen A; Karnani H; Huupponen R
Br J Clin Pharmacol; 1999 Mar; 47(3):249-54. PubMed ID: 10215747
[TBL] [Abstract][Full Text] [Related]
20. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects.
Azzaro AJ; Vandenberg CM; Blob LF; Kemper EM; Sharoky M; Oren DA; Campbell BJ
J Clin Pharmacol; 2006 Aug; 46(8):933-44. PubMed ID: 16855078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
